Xellarbio is at the forefront of drug discovery innovation with its organ-on-chip platform. This cutting-edge technology utilizes pharmaceutical-scale engineering and advanced AI to create physiologically realistic human organ models. By addressing limitations of current drug discovery methods, Xellarbio's platform enables higher predictive accuracy, cost-effective high-throughput screening, and superior risk assessment, all while significantly reducing reliance on animal testing.
We're tracking Xellarbio's market expansion
How Xellarbio's international expansion compares to its competitors
XellarbioYouBars show relative size across the companies compared.
Columns5| Company | Markets | New markets | Momentum | Activity | Expansion score |
|---|---|---|---|---|---|
 XellarbioYou | 0 | 0 | — | 0 | 0 |
Not hiring right now
Sign up to track this company and get alerted the moment something changes.
No active campaigns
Sign up to track this company and get alerted the moment something changes.
Xellar Biosystems, an AI-driven organ-on-a-chip platform company, completed over 200 million RMB Series A funding led by China Life Equity, with participation from XtalPi, Yabillion Capital, and Legend Capital.
Xellar Biosystems, an AI-driven organ-on-a-chip platform company, completed over 200 million RMB Series A funding led by China Life Equity, with participation from XtalPi, Yabillion Capital, and Legend Capital.
Be the first to find verified contacts at Xellarbio
Quick answers about Xellarbio's business, markets, and growth signals.
Pubrio glocalizes business, people, and intent data from 50+ local sources into one global graph, giving AI and revenue teams full‑market visibility.
© 2026 Pubrio. All rights reserved.
